RESULTS OF NIVOLUMAB USE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN CLINICAL PRACTICE OF THE N.N. BLOKHIN CANCER RESEARCH CENTER

ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

https://doi.org/10.37469/0507-3758-2017-63-5-724-728

Published 01.05.2017

Konstantin Laktionov⁺⁻
Kseniya Sarantseva⁺⁻
Valeriy Breder⁺⁻
Yelena Reutova⁺⁻
Denis Yudin⁺⁻
Lyudmila Laktionova⁺⁻

Konstantin Laktionov

N.N. Blokhin Cancer Research Center

Kseniya Sarantseva

N.N. Blokhin Cancer Research Center

Valeriy Breder

N.N. Blokhin Cancer Research Center

Yelena Reutova

N.N. Blokhin Cancer Research Center

Denis Yudin

N.N. Blokhin Cancer Research Center

Lyudmila Laktionova

N.N. Blokhin Cancer Research Center

##article.numberofdownloads## 27

##article.numberofviews## 70

PDF (Русский)

Keywords

IMMUNOTHERAPY
NON-SMALL CELL LUNG CANCER
CHECKPOINT INHIBITORS
NIVOLUMAB

How to Cite

Laktionov, K., Sarantseva, K., Breder, V., Reutova, Y., Yudin, D., & Laktionova, L. (2017). RESULTS OF NIVOLUMAB USE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN CLINICAL PRACTICE OF THE N.N. BLOKHIN CANCER RESEARCH CENTER. Voprosy Onkologii, 63(5), 724–728. https://doi.org/10.37469/0507-3758-2017-63-5-724-728

Abstract

The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers including non-small cell lung cancer (NSCLC). Nivolumab is the PD-1 inhibitor approved for the treatment of NSCLC to show a survival benefit in a randomised phase III trials. The experience of physicians in routine clinical practice is often different from those in a controlled clinical trial setting. The purpose of this analysis is to evaluate nivolumab use in real world setting.

https://doi.org/10.37469/0507-3758-2017-63-5-724-728

##article.numberofdownloads## 27

##article.numberofviews## 70

PDF (Русский)

References

Лактионов К.К., Саранцева К.А., Бредер В.В., Окруж-нова М.А., Перегудова М.В. Место иммуноонкологии в лечении немелкоклеточного рака легкого // Злокачественные опухоли. - 2016. - № 3. - С. 17-24.

Саранцева К.А., Лактионова Л.В., Реутова Е.В., Черненко П.А., Бредер В.В. Иммунология: иммунный ответ как ведущий защитный фактор против рака // Злокачественные опухоли. - 2016. - № 2. - С. 5-14.

Borghaei H1, Paz-Ares L., Horn L. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer // N. Engl. J. Med. - 2015. - Vol. 373 (17). - P. 1627-1639.

Brahmer J., Reckamp K.L., Baas P et al. Nivolumab versus Docetaxel in Advanced squamous-Cell Non-small-Cell Lung Cancer // N. Engl. J. Med. - 2015. - Vol. 373(2). - P. 123-135.

Brahmer J.R., Horn L., Jackman D. et al. Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer: clinical characteristics of long-term survivors. Presented at: 2017 AACR Annual Meeting; April 1-5. - Washington, DC, 2017. - Abstract CT077.

Burstein H.J., Krilov L., Aragon-Ching J.B. et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology // J. Clin. Oncol. - 2017. - Vol. 35(12). - P. 1341-1367.

Chae Y.K., Pan A., Davis A.A., Raparia K. et al. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? // Clin. Lung Cancer. - 2016. - Vol. 17 (5). - P. 350-361.

Davies M. New modalities of cancer treatment for NSCLC: Focus on immunotherapy // Cancer Manag. Res. - 2014. - № 6. - P. 63-75.

Gettinger S.N., Horn L., Gandhi L. et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer // J. Clin. Oncol. - 2015. - Vol. 33(18). - P. 2004-2012.

Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy // Nat. Rev. Cancer. - 2012. - Vol. 12. - P 252-264.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Tatyana Borisova, Arif Allakhverdiev, Yuriy Gerasimov, Nadezhda Meshcheryakova, Mikhail Dolgushin, Valeriy Breder, Konstantin Laktionov, Sevil Alieva, Stanislav Ivanov, Sergey Tkachev, Aleksey Nazarenko, S. Loraeva, STEREOTACTIC HYPO-FRACTIONAL RADIOTHERAPY OF PATIENTS WITH LUNG CANCER I-IIA CLINICAL STAGE: THE ROLE OF SUVMAX ASSESSMENT IN 18F-FDG PET/CT FOR MONITORING TREATMENT OUTCOMES , Voprosy onkologii : Vol. 63 No. 4 (2017)
Tatyana Borisova, M. Ardzinba, A. Fedorova, Valeriya Glebovskaya, Oksana Trofimova, Dimitr Marinov, Yelena Reutova, Stanislav Ivanov, Sevil Alieva, Nadezhda Meshcheryakova, Valeriy Breder, Konstantin Laktionov, Sergey Tkachev, Aleksey Nazarenko, N. Marinichenko, HIGH-TECH RADIATION THERAPY WITH LOCAL DOSE ESCALATION IN CHEMO-RADIATION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER. PREDICTORS OF EFFECTIVENESS , Voprosy onkologii : Vol. 64 No. 6 (2018)
Konstantin Laktionov, Yelena Reutova, Natalya Kormosh, Valeriy Breder, A. Gorokhov, LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT , Voprosy onkologii : Vol. 65 No. 3 (2019)
Konstantin Laktionov, Andrey Zaretskiy, Denis Yudin, Dmitriy Shagin, Valeriy Breder, REBIOPSY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AS THE BASIS OF INDIVIDUALIZED TREATMENT , Voprosy onkologii : Vol. 63 No. 3 (2017)
Konstantin Laktionov, Alla Arzumanyan, Larisa Bolotina, Valeriy Breder, Natalya Buevich, A. Danilova, Anna Zinkovskaya, Anna Kornietskaya, M. Kramchaninov, Ye. Kushniruk, Dilorom Latipova, Fedor Moiseenko, Tatyana Nikitina, Mariya Okruzhnova, Sergey Orlov, Rashida Orlova, N. Porfireva, Svetlana Protsenko, Kseniya Sarantseva, Daniil Stroyakovskiy, Yelena Filippova, Tatyana Ionova, EFFICACY OF NIVOLUMAB (NWO) DURING 2+ LINE TREATMENT AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED REFRACTORY NON-SMALL CELL LUNG CANCER: INTERIM RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY , Voprosy onkologii : Vol. 65 No. 1 (2019)
Denis Fedyaev, V. Ignateva, Yelena Derkach, Sergey Zyryanov, Konstantin Laktionov, Tatyana Semiglazova, COMPARATIVE PHARMACOECONOMIC EVALUATION OF THE USE OF AFATINIB AND GEFITINIB IN THERAPY FOR LUNG CANCER , Voprosy onkologii : Vol. 63 No. 1 (2017)
Konstantin Laktionov, Denis Yudin, Yuliya Maevskaya, Lyubov` Vladimirova , Dimitr Marinov, Merab Ardzinba, Amir Abdullaev, Irina Popova, Efficiency integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer and an activating EGFR gene mutation. , Voprosy onkologii : Vol. 67 No. 2 (2021)
Tatyana Borisova, S. Tkachev, S. Ivanov, S. Alieva, O. Trofimova, V. Glebovskaya, Valeriy Breder, K. Laktionov, Dimitr Marinov, A. Abdullaev, RADIATION THERAPY IN MULTIMODAL TREATMENT OF PATIENTS WITH PLEURAL MESOTHELIOMA. LITERATURE REVIEW AND ANALYSIS OF OWN OBSERVATIONS , Voprosy onkologii : Vol. 66 No. 5 (2020)
Valeriy Breder, Boris Dolgushin, Anatoliy Kukushkin, Igor Trofimov, Vladislav Kosyrev, Lyudmila Kostyakova, Eduard Virshke, Konstantin Laktionov, Irina Dzhanyan, M. Pitkevich, TRANSARTERIAL CHEMOEMBOLIZATION(TACE) EFFICACY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA(HCC): CAN SIGNIFICANT PROGNOSTIC FACTORS BE REVEALED? , Voprosy onkologii : Vol. 64 No. 6 (2018)
M. Natrusova, Valeriy Breder, Irina Dzhanyan, Oleg Olisov, Murad Novruzbekov, Yekaterina Moroz, P. Murashova, M. Pitkevich, Konstantin Laktionov, BRAIN METASTASES AFTER LIVER TRANSPLANTATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: THE CHOICE OF THERAPY , Voprosy onkologii : Vol. 65 No. 6 (2019)

1 2 > >>